Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality
| Authors | |
|---|---|
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Clinical Chemistry and Laboratory Medicine |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1515/cclm-2012-0833 |
| Field | Physiology |
| Keywords | advanced glycation end-products; diabetic nephropathy; fructosamine 3-kinase; glyoxalase; pentose phosphate pathway; transketolase |
| Description | Background: We hypothesized that genetic variability in genes encoding enzymes metabolizing glycolytic intermediates produced in excess under hyperglycemic conditions [i.e., transketolase ( TKT ), transaldolase, TKT-like protein 1, fructosamine 3-kinase ( FN3K ), glyoxalase 1 and glucose-6-phosphate dehydrogenase] could influence progression of diabetic nephropathy (DN) and diabetesrelated morbidity and mortality. Methods: A total of 19 single nucleotide polymorphisms (SNPs) in six candidate genes were studied in 314 type 2 diabetic subjects with variable stage of kidney disease (normo- and microalbuminuria, proteinuria, end-stage renal disease). SNP selection criteria were based on known functional effect and gene coverage. SNPs were detected using polymerase chain reaction based methods. Subjects were followed up for median of 38 months. Time-to-event analysis considered three end-points: 1) DN progression by at least one stage; 2) major cardiovascular event; and 3) all-cause mortality. Results: We found combined effect of TKT SNP rs11130362 and FN3K SNP rs1056534 on DN progression (p < 0.01). Additionally, TKT rs3736156 alone and also in combination with the previous two SNPs exhibited significant effect on incidence of major cardiovascular events (p < 0.01 and p = 0.01, respectively). Conclusions: Genetic variability in rate-limiting enzymes of pathways proposed to confer hypothetical protection against hyperglycemia might act as an important determinant of hyperglycemia toxicity in long-standing diabetes. |
| Related projects: |